Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:49 (3 January), doi:10.1136/bmj.328.7430.49
| The first 150 words of the full text of this article appear below. |
EDITORThe public in general and NHS patients in particular ought to benefit from advances in knowledge about prevention, treatment, rehabilitation, and care. Important progress has been made in disseminating relevant information through the National Electronic Library for Health and the National Institute for Clinical Excellence (NICE), but more investment in randomised clinical trials is needed to test the validity of hypotheses and findings derived from basic research.
The Medical Research Council remains the largest public funder of clinical trials and has steadily increased its investment in randomised clinical trials (figure). But the total numbers of non-commercial randomised trials in the United Kingdom has declined worryingly, including those supported by the NHS research and development programme.1 Given the needs of the NHS, the overall public support for randomised clinical trials remains modest compared with that for other areas of biomedical science. Substantial investment is needed in infrastructure,
Colin Blakemore, chief executive
Medical Research Council, London W1B 1AL colin.blakemore@headoffice.mrc.ac.uk
Iain Chalmers, coordinator
James Lind Initiative, Oxford OX2 7LG ichalmers@jameslindlibrary.org